SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the potential impact of a failed Alzheimer's drug trial on its stock, despite its dominance in the obesity market with drugs like Wegovy, where community members speculate on the possibility of a price war. Some investors view the dip as a buying opportunity, emphasizing the company's strong fundamentals and long-term potential in the weight loss sector, while others worry about competition from other pharmaceutical companies. There is also discussion around potential acquisitions and partnerships.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending due to reports of a potential extension of Obamacare subsidies, sparking both bullish and bearish sentiments within the community. Bulls anticipate significant gains if the subsidies are extended, while bears express concerns about the company's long-term viability and potential challenges in improving medical loss ratios. Community members are actively discussing potential price targets, entry points, and the overall impact of policy changes on the healthcare sector.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid discussions around its potential involvement in the Jeffrey Epstein case and differing opinions on Jamie Dimon's stance on crypto. The community is divided, with some calling for boycotts and others defending the bank's position; also, there is discussion surrounding JPM's recent moves in the crypto space, with some interpreting these moves as hypocritical.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as community members discuss the potential impact of its new Gemini 3 model, with some suggesting it could be a game-changer in the AI race and drive further gains. Bullish sentiment is fueled by positive analyst ratings and Waymo's expansion, while some traders are closely watching for a potential pullback after the recent surge.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to robotaxi revenue growth and global expansion milestones, including approvals for driverless operations in Abu Dhabi and partnerships with Uber and Grab. The community is buzzing about the company's potential to monetize AI and compete with Tesla in the robotaxi market. Discussions also highlight WeRide's strategic partnerships and the rapid development of China's autonomous driving technology.

Monad

Monad is trending as its public mainnet launch and token listing approaches, sparking excitement and debate within the crypto community. Discussions revolve around the token distribution process, potential for profit, and where to purchase, alongside speculation about a possible initial price surge and subsequent dip. Some users express concerns about it being a potential scam, while others highlight its listing on Coinbase as a positive sign.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending as its Qwen AI app reached 10 million downloads, driving optimism despite broader market AI skepticism. Community members are actively discussing the app's potential to rival ChatGPT and the implications for Alibaba's AI strategy. The news has sparked debate about the stock's valuation and future prospects within the competitive tech landscape.

Molina Healthcare, Inc. engages in the provision of health care services. It operates through the following segments: Medicaid, Medicare, Marketplace, and Other. The company was founded by C. David Molina in 1980 and is headquartered in Long Beach, CA.

Molina Healthcare Inc

MOH is trending as the community discusses its recent rating adjustments from various firms and a significant price drop following disappointing earnings, which missed estimates due to rising medical costs. Community members are weighing the potential for a rebound, citing the company's balance sheet, while others express concerns about sector-wide challenges and potential downgrades. Discussions also revolve around the impact of Medicaid and Medicare policies on the company's revenue streams.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to Novo Nordisk's Alzheimer's drug trial failure, boosting interest in BIIB's CNS pipeline. The community is discussing Biogen's potential upside in the Alzheimer's space and recent analyst upgrades. Biogen's strategic focus on CNS and Alzheimer's treatments is being highlighted amid renewed interest in the sector.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

MSI is trending due to community focus on technical analysis, particularly positive divergence and significant dark pool activity suggesting a potential oversold bounce. Traders are pointing to a large dark pool print as a sign of a bottom and reversal. The stock's oversold condition and potential for a bounce are key talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve research firms that are covering the firm, MarketBeat...

Solid Biosciences (NASDAQ:SLDB) Price Target Cut to $14.00 by Analysts at Citigroup

Citigroup dropped their price objective on shares of Solid Biosciences from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Wednesday...

JPMorgan Chase & Co. Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price

JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $13.00 to $11.00 and set an "overweight" rating for the company in a report on Wednesday...

Solid Biosciences drew heightened retail chatter on Tuesday following&nbsp;approvals for human trials by U.S. and Canadian regulators to test its gene therapy,&nbsp; SGT-501, for a life-threatening heart rhythm condition&nbsp;called catecholaminergic polymorphic ventricular tachycardia (CPVT).This inherited disorder commonly affects children and young adults who experience dangerous arrhythmias when stressed or exercising with no existing FDA-approved treatments available in the U.S.Shares of the Charlestown, Massachusetts-based company, which ended Tuesday more than 6% higher, gained over 4% in after-hours trading following the announcement.Solid Biosciences&nbsp;plans to launch a Phase 1b trial later this year to determine the safety and effectiveness of the therapy.&nbsp;SGT-501 holds Orphan Drug and Rare Pediatric Disease designations in the U.S. that offer development and commercialization incentives, including extended exclusivity, and accelerated reviews when the drug candidate enters an approval application stage.The treatment employs a viral tool to introduce a functional CASQ2 gene into cardiac muscle cells.&nbsp;The CASQ2 gene&nbsp;encodes a protein essential for heart cells to maintain&nbsp;regular calcium release and uptake during each heartbeat.&nbsp;The genetic changes found in CPVT patients result in&nbsp;a disruption of&nbsp;calcium flow, which triggers abnormal heart rhythms.The company is also advancing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD).&nbsp;Last week, Citi initiated coverage on Solid with a&nbsp;‘Buy’ rating and a $14 price target, citing favorable risk-reward dynamics and a cleaner safety profile for SGT-003 compared to Sarepta’s Elevidys, which has been&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-pauses-dmd-gene-therapy-trial-after-second-death-retail-traders-brush-off-risk/chlnJFARRbY">under scrutiny</a> following reports of liver-related fatalities.H.C. Wainwright also maintained a ‘Buy’ rating on Solid, calling SGT-003 the most promising DMD gene therapy currently in development or on the market.On Stocktwits, retail sentiment for Solid was ‘extremely bullish’ amid ‘extremely high’ message volume.One user reflected on a missed opportunity, noting they “hesitated to add more” at $2.40 and now “regret it,” saying they should have purchased at least 800 shares.&nbsp;<stembedurl>https://stocktwits.com/Rolex53/message/620276017</stembedurl>Another user questioned whether the post-news spike to $5.80 was the peak, acknowledging the announcement as “critical confirmation of our product pipeline,” but also cautioning that it’s not the same as fast-tracking or trial success.<stembedurl>https://stocktwits.com/The_Red_Fox/message/620258395</stembedurl><a href="https://stocktwits.com/symbol/SLDB">SLDB’s stock</a> has risen 34.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Solid Biosciences (SLDB) got approvals for human trials by U.S. and Canadian regulators to test its gene therapy,  SGT-501/ Photo credit: Getty Images

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

The company plans to begin a Phase 1b trial of SGT-501 later this year, targeting CPVT, a rare and potentially fatal arrhythmia in children and young adults with no current FDA-approved therapies.

Equity

Stock market today: S&P 500 in Q1 loss despite jump; 'liberation day' tariffs loom

Investing.com-- The S&P 500 closed higher Monday, as a dip to six-month lows drew support, but the index ended the first quarter lower just days ahead of President Donald Trump’s April 2 "liberation day" deadline to impose more reciprocal tariffs. 

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended gains in after-hours trading. On Stocktwits, the ticker's retail followers jumped by 11%.Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.Interim 90-day biopsy data from the Phase 1/2 trial showed:<ul style="list-style-type:square;"><li>110% average microdystrophin expression (via western blot) in the first three participants</li><li>Improvements in multiple biomarkers, indicating better muscle health and resilience</li><li>SGT-003 was well-tolerated, with no serious adverse events or signs of major complications like thrombotic microangiopathy</li></ul>&nbsp;Adverse events included nausea, vomiting, fever, and transient platelet declines—which the company said were typical for adeno-associated virus gene therapy—but none required additional immunomodulatory treatments.Following the data, according to The Fly, Chardan raised its price target on Solid Biosciences to $16 from $15, implying more than a 200% upside from Tuesday’s close.&nbsp;The research firm also increased the therapy's probability of success to 48%, citing strong early efficacy signals and manageable safety.Retail sentiment on Stocktwits turned 'extremely bullish,' with message volume skyrocketing over 5,500% to the highest level in three months.One user commented that the "real appreciation" for the stock will start "once the day traders leave."<stembedurl>https://stocktwits.com/pharmd2828/message/604696890</stembedurl>Another suggested the stock could "double in no time" based on "pretty compelling data."<stembedurl>https://stocktwits.com/iSmith/message/604695964</stembedurl>Early results from a Stocktwits poll showed 49% of respondents believe SGT-003 could be a blockbuster, while 20% think it's "just hype."<figure class="image"><img style="aspect-ratio:1314/1062;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SLDB_poll_and_sentiment_meter_on_Feb_18_7c2cbe8810.png" alt="SLDB poll and sentiment meter on Feb 18.png" width="1314" height="1062"><figcaption>SLDB poll and sentiment meter on Feb 18 | source: Stocktwits</figcaption></figure>Separately, Solid Biosciences announced a $200 million underwritten offering, pricing 35.7 million common shares at $4.03 per share and 13.9 million pre-funded warrants at $4.029 apiece. The offering is set to close on Wednesday.According to Koyfin, short interest on SLDB has climbed from 4.4% at the start of the year to 6.6%.<a href="https://stocktwits.com/symbol/SSRM">Solid Biosciences stock</a> is now up over 31% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?

Early-stage data from the company's gene therapy candidate SGT-003 for Duchenne muscular dystrophy (DMD) showed encouraging results.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases...

Solid Biosciences' SGT-003 receives rare pediatric disease designation

Duchenne is a genetic disorder, primarily affecting boys and is known to be fatal. This disease is claimed to affect roughly one in every 3,500 to 5,000 live
The post Solid Biosciences' SGT-003...

Solid Biosciences (SLDB, $12.44) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This indicator may be signaling that SLDB's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

SLDB
Solid Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLDB News

SLDBSolid Biosciences Inc